SELUTION DeNovo Trial — SCAI 2026 Highlights
SELUTION DeNovo Trial — SCAI 2026 Highlights
Source: SCAI 2026
Date: April 23, 2026
Sirolimus drug-coated balloon (DCB) was noninferior to DES in ACS patients
* No difference in:
* cardiac death
* MI
* revascularization
* stroke or major bleeding
* Key insight:
* DCB strategy is safe option to avoid stenting
* “leave nothing behind” concept
* Limitations:
* STEMI excluded
* long-term benefit still under evaluation (5 years)
Bottom Line
DCB = viable alternative to DES in ACS
similar short-term outcomes
long-term advantage still uncertain